Atossa Therapeutics Inc (ATOS) Stock AnalysisATOSStock AnalysisAtossa Therapeutics Inc

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Atossa Therapeutics Inc is a good buy right now due to its current price of $2.58, which is significantly lower than the analyst price target of $12, indicating a potential upside of 366%. Additionally, the stock has shown a positive trend with a 20-day change of +24.64%, suggesting a recovery momentum. However, the main risk is the ongoing losses, with a net income of -$8,491,000 reported for Q2 2026, which could impact future financing and investor confidence.

1 analysts cover ATOS: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 18.33.